版本:
中国

BRIEF-Basilea Pharmaceutica awarded $54.8 mln of additional funding by BARDA

June 13 BASILEA PHARMACEUTICA AG:

* BASILEA AWARDED USD 54.8 MILLION OF ADDITIONAL FUNDING BY BARDA TO SUPPORT PHASE 3 DEVELOPMENT OF CEFTOBIPROLE

* ‍TOTAL POTENTIAL FUNDING OF UP TO APPROXIMATELY USD 108 MILLION UNDER CONTRACT WILL ENABLE BASILEA TO CONDUCT TWO CLINICAL PHASE 3 STUDIES​

* ‍TOTAL VALUE OF CONTRACT COULD REACH APPROXIMATELY USD 108 MILLION OVER A PERIOD OF 4.5 YEARS IF PRE-DEFINED MILESTONES ARE MET​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐